ne of the world’s largest drug makers is testing a radical new approach to treating depression — by dialing down inflammation in the body, rather than tinkering with chemicals in the brain.If it works, it’s likely to be expensive, have serious side effects, and help only a subset of patients. But it could also open the door to a whole new field of drug development for other psychiatric conditions, including bipolar disorder, anxiety disorders, and schizophrenia, all of which might be propelled, at least in part, by excess immune activity in the brain.

Source: Could tamping down inflammation lift the fog of depression?